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Abstract
Background: The PTEN/Phosphatidylinositol 3’-kinase (PI3-kinase) growth factor signaling pathway plays a critical
role in epithelial tumor development in a multitude of tissue types. Deletion of the Pten tumor suppressor gene in
murine urothelial cells in vivo results in upregulation of cyclin-dependent kinase inhibitor p21. We have previously
shown in mice that p21 expression blocks an increase in urothelial cell proliferation due to Pten deletion. In this
study, we utilized human urothelial carcinoma cells UMUC-3 and UMUC-14 to identify the signaling pathways
downstream of PI3-kinase that regulate p21.
Methods: Cells were treated with a combination of PI3-kinase stimulating growth factors and kinase inhibitors, or
transfected with exogenous genes in order to identify the signaling events that are necessary for p21 induction.
Mice with conditional deletion of Pten in bladder urothelium were also examined for evidence of PI3-kinase
pathway signaling events that affect p21 expression.
Results: When cells were treated with PI3-kinase activating growth factors EGF or PDGF, we found that p21 levels
increased, in a manner similar to that observed in mice. We used the inhibitors LY294002, Akti-1/2, and rapamycin,
to show that p21 induction is dependent upon PI3-kinase and AKT activity, and partially dependent on mTOR. We
treated the cells with proteasome inhibitor MG-132 and found that p21 may be degraded in the proteasome to
regulate protein levels. Importantly, our findings show that GSK-3b plays a role in diminishing p21 levels in cells.
Treatment of cells with the GSK-3b inhibitor SB-216763 increased p21 levels, while exogenous expression of GSK-3b
caused a decrease in p21, indicating that GSK-3b actively reduces p21 levels. We found that a combined treatment
of LY294002 and SB-216763 improved the cytotoxic effect against UMUC-3 and UMUC-14 carcinoma cells over
LY294002 alone, suggesting potential therapeutic uses for GSK-3b inhibitors. Immunohistochemical staining in
bladders from wild-type and Pten-deleted mice indicated that GSK-3b inhibitory phosphorylation increases when
Pten is deleted.
Conclusion: PI3-kinase and AKT cause an upregulation of p21 by suppressing GSK-3b activity and activating mTOR
in both cultured human urothelial carcinoma cells and mouse urothelial cells in vivo.
Background
It has been well established that the phosphatase and
tensin homologue deleted on chromosome 10 (PTEN)
gene plays an important role in suppressing tumor
development in multiple human cell types and organs
such as the endometrium, brain, skin, and prostate [1].
S t u d i e si nt h el a s tf e wy e a r sh a v es h o w nt h a tPTEN
mutation is also associated with bladder cancer [2,3].
Multiple studies utilizing tissue microarray analysis and
immunohistochemistry have shown that PTEN expres-
sion is diminished in late bladder cancers of higher
tumor stage and grade [4-7]. Screens of human bladder
cancer cell lines have also revealed that PTEN expres-
sion is often lost [8-10]. Exogenous expression of PTEN
in bladder cancer cells results in decreased invasiveness
[11], providing an explanation for why PTEN loss in
advanced cancers is common. The finding that PTEN
expression is reduced in bladder cancer is consistent
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migration but also in suppressing cell proliferation and
apoptosis, as well as maintaining genomic integrity [1].
The principal manner in which PTEN appears to sup-
press cell growth is through its lipid phosphatase activity
[12]. PTEN removes the phosphate from the D3 position
of phosphatidylinositol-3,4,5-trisphosphate (PIP3)t og e n -
erate phosphatidylinositol-4,5-bisphosphate (PIP2) [13].
The reverse reaction is catalyzed by Class I phosphatidy-
linositol 3-kinases (PI3-kinases) in response to activation
by receptor tyrosine kinases and G-protein coupled
receptors [14]. PIP3 in the plasma membrane generated
by PI3-kinase leads to the recruitment and activation of
the AKT serine/threonine kinase [15]. AKT in turn phos-
phorylates numerous substrates that lead to cell prolif-
eration, growth, and survival. One known substrate of
AKT is glycogen synthase kinase-3 beta (GSK-3b) [16], a
serine-threonine kinase that plays an important role in
insulin signaling. Phosphorylation of GSK-3b by AKT
inactivates its kinase activity[ 1 6 ] .T h e r ei sas e c o n di s o -
form of glycogen synthase kinase called GSK-3a that is
also inhibited by phosphorylation by AKT, but its func-
tion is less clear [17]. Another important kinase that is
activated downstream of AKT is mTOR; it mediates an
increase in protein synthesis and cell growth, among
other functions [18].
In a previous study, we generated mice in which Pten
was conditionally deleted in bladder urothelium in order
to study the effects on tumorigenesis and PI3-kinase sig-
naling [19]. Notably, we found that the cyclin-dependent
kinase p21 was consistently upregulated in the PTEN-defi-
cient cells. As in normal urothelial cells, the p21 remained
in the nucleus, indicating that activation of the PI3-kinase
pathway was not leading to relocalization of p21 to the
cytoplasm [20]. Other subsequent studies in the liver [21]
and in kidney cells [22] have also shown that activation of
the PI3-kinase/AKT pathway and PTEN knockdown lead
to an increase in p21 levels.
This increase in p21 levels is important because it sup-
presses bladder urothelial proliferation elicited by the Pten
deletion [19], and may contribute to reduced tumorigen-
esis in the bladder. The p21 protein inhibits cell prolifera-
tion by functioning as a cyclin-dependent kinase inhibitor
[23], and p21 exhibits tumor suppressor functions as
shown by the finding that p21-/- 129Sv/C57Bl6 mice
develop spontaneous tumors at 16 months of age [24].
Immunohistochemical studies of human tumors suggest
that the p21 induction we observed in mice may occur in
human bladder cells as well, since p21 levels are increased
in bladder tumors [25,26] and in transitional cell carci-
noma cell lines [27] compared to normal urothelium.
Importantly, bladder tumors with increased grade [25,28]
and/or stage [25,29] have reduced p21 levels compared to
lower grade or stage noninvasive tumors, suggesting that
p21 expression is selectively lost in advanced tumors.
Furthermore, tumors that have lost p21 expression are
associated with decreased probability of survival [30].
In many cell types, PI3-kinase/AKT signaling leads to
increased cell proliferation, so the fact that it induces
p21 and inhibits cell proliferation in bladder urothelial
cells is surprising. The commonly accepted model that
PI3-kinase/AKT signaling induces cell cycle progression
does not apply to urothelial cells. Understanding how
urothelial cells will respond to stimulation or inhibition
of this signaling pathway is important for tailoring ther-
apy for tumors originating from the urothelium. We
therefore aimed to elucidate the mechanism by which
PI3-kinase/AKT signaling leads to p21 increase in
human urothelial cells.
Methods
Cell culture
>Human UMUC-3 urinary bladder transitional cell car-
cinoma cells were obtained from the American Type
Culture Collection (Manassas, VA). The cells were pas-
saged in DMEM (Hyclone) supplemented with 10%
newborn calf serum (Hyclone), penicillin (100 U/ml)
and streptomycin (100 mg/L) (Sigma) in a humidified
incubator containing 5% CO2 and maintained at 37°C.
Human UMUC-14 urothelial carcinoma cells were gen-
erously provided by Herbert Grossman (MD Anderson
Cancer Center). These cells were maintained in DMEM
with 10% fetal calf serum (Hyclone) and penicillin (100
U/mL)/streptomycin (100 mg/L).
Materials
PDGF-BB and EGF were obtained from Peprotech (Rocky
Hill, NJ). LY294002, MG-132, and SB-216763 were pur-
chased from Enzo Life Sciences (Plymouth Meeting, PA).
Akti-1/2 was purchased from EMD Biosciences (San
Diego, CA). Rapamycin was obtained from LKT Labs (St.
Paul, MN). The monoclonal p21 antibody was obtained
from BD Biosciences (San Diego, CA). The phospho-AKT
ser 473, GAPDH, b-catenin, GSK-3a, GSK-3b, and phos-
pho-GSK-3 a/b ser 9/21 antibodies were purchased from
Cell Signaling Technology (Danvers, MA). The 12G10 a-
tubulin and a-actin antibodies were obtained from the
Developmental Studies Hybridoma Bank (University of
I o w a ) .T h ea n t i - p h o s p h o - H i s t o n eH 3a n t i b o d yw a s
obtained from Upstate (Lake Placid, NY). The mammalian
expression vectors GSK3 alpha pMT2 (15896) and HA
GSK3 beta wt pcDNA3 (14753) were purchased from
Addgene (Cambridge, MA). siRNA (siGENOME smart-
pool) was purchased from Dharmacon (Lafayette, CO).
Western blotting
Cells were treated as described and then washed in phos-
phate-buffered saline. Cells were lysed in ice-cold RIPA
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1 mM EDTA pH8, 1 mM PMSF, 1 mM sodium orthova-
nadate, 1 mM sodium fluoride). After centrifugation at
13,000 rpm for 5 min, supernatants were isolated, and an
aliquot was measured for protein concentration using a
BCA Assay (Pierce). The lysates were mixed in a 1:1 ratio
with 2 × electrophoresis sample buffer (125 mM Tris-Cl
pH 6.8, 20% glycerol, 4% SDS, 10% beta mercaptoethanol,
0.0025% bromophenol blue). Approximately 25 μgo f
protein from each sample was loaded into each well for
SDS-PAGE, and the proteins were transferred to nitrocel-
lulose membranes (Protran). Membranes were rocked for
1 h at room temperature in blocking buffer (3% nonfat
milk dissolved in TBS-T: 50 mM Tris pH 8, 137.5 mM
NaCl, 2.7 mM KCl, 0.08% Tween 20). Membranes were
incubated with primary antibody diluted in either 3%
milk/TBS-T (tubulin antibody) or 5% BSA/TBS-T (all
other antibodies) for 1 h at room temperature. Then
membranes were incubated with goat secondary antibody
conjugated to HRP (Jackson ImmunoResearch Labs)
diluted in 3% milk/TBS-T for 1 h at room temperature.
Finally blots were washed in TBS-T, exposed to chemilu-
minescent substrate (Immobilon) and visualized on an
imaging system (AlphaInnotech Fluorchem). Spot densi-
tometry quantitation was performed, by subtracting
background signal from each band of interest and divid-
ing that value by the background-subtracted tubulin sig-
nal for the same lane, in order to normalize for protein
loading.
RNA interference
4000 cells were plated in each well in a 96 well cell culture
plate. Cells were transfected with siRNA (Dharmacon)
using RNAiMAX (Invitrogen) in antibiotic-free medium.
MTS assay
4000 cells were plated in each well in 96 well cell culture
plates. The following day, cells were treated with drugs as
described in the Results. Every type of treatment was per-
formed in quadruplicate wells. After 48 or 72 h, cell viabi-
lity was measured using the Promega CellTiter 96
Aqueous Non-Radioactive Cell Proliferation Assay (MTS).
1 to 3 h after the MTS solution was added, the absorbance
of the wells was measured in a plate reader at 450 nm.
Mice
All mice were maintained in a specific pathogen free
animal facility at Harvard Medical School. Research was
performed in accordance with guidelines and policies as
set by the Harvard Medical Area Standing Committee
on Animals (approval reference #02460). Mice homozy-
gous for floxed Pten exon 5 (Pten
loxp/loxp)[ 3 1 ]w e r e
c r o s s e dt om i c et r a n s g e n i cf o rFabpl-Cre [32]. F1
Pten
loxp/+;Fabpl-Cre+ mice were crossed with Pten
loxp/
loxp mice to obtain Pten
loxp/loxp;Fabpl-Cre+ mice.
Immunohistochemistry
Murine bladders were fixed in 4% paraformaldehyde/PBS
and stored in 70% ethanol until they were embedded in
paraffin and sectioned (Harvard Rodent Histopathology
Core). Sections were deparaffinized and subject to 0.5%
hydrogen peroxide/PBS treatment for 10 min. Antigen
retrieval was accomplished by boiling sections in 0.01 M
Citrate pH 6 buffer for 10 min in a microwave. Sections
were blocked in 3% donkey serum/PBS/0.2% triton-X. Pri-
mary antibody was added in blocking solution for 2 h at
room temperature or overnight at 4C, followed by washes
and incubation with biotinylated secondary antibody for
1 h at room temperature. The Vectastain ABC system
(Vector Labs) was used in conjunction with either Vector
Red substrate for alkaline phosphatase or 3,3’-diaminoben-
zidine (DAB) substrate for peroxidase. All sections were
further stained with hematoxylin, dehydrated, and
mounted with Permount™.
Transfections
Cells were counted, and 2 × 10
5 cells were plated in 60
mm dishes. The following day 2 μgo fD N Aw a sm i x e d
with 6 μl of Fugene in Opti-MEM solution (Invitrogen).
After 15 min, the mixture was dropped onto cells and left
to incubate for 48 h. Cells were then washed with PBS and
depending on treatment, some cells were incubated in
serum-free DMEM for 24 additional hours. Cells were
lysed and subject to western blotting as described above.
Statistical analyses
All statistical tests (Oneway ANOVA, Tukey-Kramer
HSD, and Student’st - t e s t )w e r ed o n eu s i n gJ M P 9
software.
Results
In our previous studies, we found that deletion of Pten in
murine bladder epithelium leads to an increase in p21
expression, and that the p21 mediates a significant
decrease in cell proliferation [19]. We therefore investi-
gated whether p21 was similarly induced in human
urothelial carcinoma cells by signaling through the PI3-
kinase pathway. We selected two cell lines: UMUC-3
(PTEN negative) and UMUC-14 (PTEN positive)for our
studies. These cell lines were originally derived from two
independent urothelial carcinomas. The cells were serum
starved for 24 hours in order to attenuate growth factor
signaling. Then, we treated cells with two different
growth factors that are known to activate PI3-kinase: epi-
dermal growth factor (EGF) and platelet-derived growth
factor (PDGF) [33,34]. When treated with EGF, p21 levels
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cells do express PTEN protein, the cell line is still clearly
responsive to growth factor signaling. We also treated
both cell lines with PDGF because if the p21 induction
was dependent on PI3-kinase, then signaling through
multiple growth factor receptors should induce p21.
PDGF did induce p21 in both cell types, especially at the
concentration of 100 ng/ml (Figure 1B).
It was important to see if the increased p21 in the cells
affects cell proliferation, so we transfected the UMUC-3
cells with either control siRNA or p21 siRNA to knock
down p21 expression. Two days after transfection, cells
were washed in PBS and serum starved for 24 hours. Then
E G F( 1 0n g / m l )w a sa d d e dt os o m eo ft h ew e l l sf o r2 4
hours, and an MTS assay was run to measure cell prolif-
eration. As seen in Figure 1C, EGF treatment actually
significantly decreased the number of viable cells, and
knock down of p21 prevented this effect of EGF (ANOVA;
p = .002), showing that the induction of p21 in response to
EGF results in reduced cell proliferation.
In order to verify whether this p21 induction was
dependent on PI3-kinase and AKT signaling, cells were
stimulated with EGF in the presence or absence of
LY294002, a PI3-kinase inhibitor, or Akti-1/2, an AKT
inhibitor (Figure 2). Western blotting showed that p21
induction did not occur in the presence of AKT inhibitor,
and there was very weak p21 induction in the presence of
LY294002, indicating that p21 induction was in fact
dependent on PI3-kinase and AKT activity. We con-
firmed that the inhibitors were effective at blocking sig-
naling by testing for AKT phosphorylation at the critical
activation site, serine 473 (Figure 2A).
AKT is known to cause downstream mTOR activation
[1], and since mTOR increases translation of many pro-
teins, we tested if mTOR was responsible for the increased
p21 levels in the urothelial cell lines stimulated with
growth factors. We pre-treated some of the UMUC-3 cells
for one hour with 12.5 nM rapamycin, an mTOR inhibi-
tor, and then stimulated the cells with EGF. Immunoblot-
ting for phosphorylated ribosomal S6 protein, a critical
downstream substrate that mediates mTOR’se f f e c t so n
protein synthesis, verified that the rapamycin suppressed
mTOR activity (Figure 3A). We found that p21 was still
induced by EGF in the presence of rapamycin in the
UMUC-14 cells and possibly also in the UMUC-3 cells
(Figure 3A and 3B), although to a reduced extent. This
indicated that the p21 induction caused by the PI3-kinase
pathway is partially mediated by mTOR.
Since the PI3-kinase/AKT signaling pathway is known
to inhibit GSK-3b activity [16], and GSK-3b has been
reported to cause the degradation of other proteins such
as b catenin [17] and SMAD1 [35], we decided to inves-
tigate its involvement in p21 regulation in bladder cells.
First, we examined if PI3-kinase/AKT signaling results
in GSK-3 inhibition in UMUC-3 and UMUC-14 cells.
While most studies have examined the role of GSK-3b
in this pathway, the function of the GSK-3a isoform is
less clear, so we investigated the status of both isoforms.
AKT has been shown to directly phosphorylate GSK-3a
and b at serines 9 and 21 [16], respectively, resulting in
an inhibition in GSK-3 activity. Treatment of both
UMUC-3 and UMUC-14 cells with EGF resulted in
increased phosphorylation of GSK-3a and b at serine 9
and 21(Figure 4A and 4B). In both cell types, the phos-
phorylation of GSK-3a and b was PI3-kinase and AKT
dependent. This result confirmed that GSK-3 is inhib-
ited by PI3-kinase/AKT in human bladder cells and led
to our subsequent investigation to determine if the
GSK-3 inhibition affects p21 levels.
In order to ascertain if GSK-3 inhibition causes an
increase in p21 in bladder cells, UMUC-3 and UMUC-14
cells were serum starved for 24 hours to suppress PI3-
kinase signaling and thereby promote GSK-3 activity. The
cells were then treated with the GSK-3 inhibitor SB216763
over five hours. Levels of p21 were initially low after
serum starvation, but increased in response to SB216763
treatment (Figure 5A), indicating that GSK-3 activity nega-
tively regulates p21 expression. UMUC-3 cells contain a
mutated p53, so the p21 induction in response to
SB216763 is not p53-dependent in these cells.
In order to more directly test the effects of GSK-3a and
b individually on p21, we transiently transfected GSK-3
expression vectors into UMUC-14 cells for 48 hours. The
exogenous GSK-3b has a slightly higher molecular weight
than does endogenous GSK-3b due to the presence of a
C-terminal HA tag (Figure 5B). When p21 levels were
tested in the presence of 10% fetal calf serum, no effects of
GSK-3 expression on p21 were evident. However, when
transfected cells were serum starved for 24 hours in order
to minimize GSK-3 inhibition by AKT, exogenous expres-
sion of GSK-3b resulted in a massive decrease in p21
levels (Figure 5B). GSK-3a had a lesser effect but also
appeared to diminish p21 levels in experimental replicates.
This indicates that GSK-3b downregulates p21, but that
activity is inhibited in the presence of serum and an active
PI3-kinase pathway. Interestingly, b catenin levels were
unaffected by exogenous GSK-3 expression (Figure 5B),
which suggests that b c a t e n i nd i dn o tp l a yar o l ei nt h e
induction of p21.
The ability of the GSK-3 inhibitor SB216763 to induce
p21 led us to speculate that SB216763 should inhibit
urothelial carcinoma cell proliferation. We further
hypothesized that the combination of SB216763 with a
PI3-kinase inhibitor such as LY294002 should more effec-
tively inhibit cell proliferation and/or induce cytotoxicity
than LY294002 alone. In order to test these hypotheses,
w et r e a t e dU M U C - 3a n dU M U C - 1 4c e l l sw i t hv a r i o u s
concentrations of SB216763 in the presence or absence of
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Figure 1 Growth factors induce p21 and inhibit proliferation in bladder carcinoma cells. UMUC-3 and UMUC-14 human urothelial
carcinoma cell lines were serum starved for 24 hours and then stimulated with growth factors. (A) Cells were lysed at intervals after addition of
10 ng/ml EGF, and proteins were harvested for immunoblotting against p21 and a-tubulin. Quantitation of relative p21 signal normalized to
tubulin after 180 minute EGF treatment is shown in the graphs. There were 4 replicates of each treatment for the UMUC-3 cells and 3 replicates
of the UMUC-14 cells. Error bars represent S.E.M. (B) UMUC-3 cells were treated with varying concentrations of PDGF for 90 minutes and then
were harvested. Lysates were immunoblotted for expression of p21 and phosphorylation levels of AKT at serine 473. Relative levels of p21
normalized to tubulin after 90 minutes of 100 ng/ml PDGF treatment is shown in the graphs for both UMUC-3 and UMUC-14 cells. There were 4
replicates of each treatment. (C) UMUC-3 cells were transfected with control or p21 siRNA and 48 hours later, cells were serum starved for 24
hours. Then 10 ng/ml EGF was added to half of the wells and 24 hours later an MTS assay was run. * significantly different from all other
treatments, p = .002.
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Page 5 of 13LY294002. After 48 hours (for UMUC-14 cells) or 72
hours (for UMUC-3 cells), we performed an MTS assay to
measure cell viability (Figure 5C). The UMUC-3 cells had
a longer drug treatment because they showed relatively lit-
tle cytotoxicity at 48 hours. After 72 hours, the UMUC-3
cells did not show significant decreases in viability due to
treatment with LY294002 alone or SB216763 alone, even
at the highest concentrations used in this assay, although
there was a trend toward decreased viability for both
drugs. A combination of the two drugs was most effective
for cell cytotoxicity; 2 μM LY294002 plus SB216763 at any
tested concentration caused significant decreases in
UMUC-3 cell viability compared to 2 μM LY294002 alone
(Oneway ANOVA; p < .0001). While treatment of the
UMUC-14 cells with 2 μM LY294002 alone had no signifi-
cant effect on cell viability compared to untreated cells,
there was a dose-dependent cytotoxicity response to
SB216763 alone (Oneway ANOVA; p < .0001), and there
was a significant decrease in cell viability at 10 μM
SB216763 (Tukey-Kramer HSD; p = .0004) and at 40 μM
SB216763 (Tukey-Kramer HSD; p < .0001) compared to
the untreated control cells. A combination of the two
drugs was once again more effective for cytotoxicity; when
2 μM LY294002 was added to the UMUC-14 cells
together with 10 μM SB216763, there was a significant
further decrease in cell viability compared to LY294002
alone (Oneway ANOVA; p < .0001; Tukey-Kramer HSD;
p = .0007). In addition, there was significantly more cyto-
toxicity at 40 μM SB216763 when comparing cells in the
presence of LY294002 compared to the cells that received
no LY294004 (Student’s t-test; p = .02). This suggests that
increased inhibition of cell viability can be attained with a
combination of the LY294002 PI3-kinase inhibitor and the
SB216763 GSK-3 inhibitor.
GSK-3b is known to directly phosphorylate substrates
leading to ubiquitylation and subsequent proteasome
dependent degradation of those proteins. It is unclear,
however, if p21 is targeted for proteasomal destruction in
these cells. If GSK-3 was regulating p21 in this manner in
these cell lines, then we should expect to see evidence
that the proteasome regulates p21 levels. We found that
serum starvation to activate GSK-3, followed by protea-
some inhibition using MG-132 leads to an increase in
p21 in both UMUC-3 and UMUC-14 cells (Figure 6),
suggesting that p21 levels are regulated by proteasomal
degradation.
Given the evidence that GSK-3b inhibition causes ele-
vated p21 levels in PI3-kinase stimulated human urothelial
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Figure 2 EGF induces p21 in a PI3-kinase and AKT dependent manner. (A) UMUC-3 cells were pre-treated for one hour with PI3-kinase
inhibitor LY294002 (30 μM) or AKT inhibitor AKTi-1/2 (10 μM) and then stimulated with EGF over a 180 minute time course. Cells were
harvested at times shown and probed for expression of p21 and phosphorylated AKT serine 473. (B) Quantitation of relative p21 signal
normalized to tubulin after 180 minute EGF treatment in the presence or absence of pretreatment with LY294002 or Akti-1/2 is shown. Four
replicates of each treatment were tested. Error bars represent S.E.M.
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Page 6 of 13cells, we examined if GSK-3b is also inhibited in mice that
are conditionally deficient for Pten (Fabpl-Cre;Pten
loxp/loxp)
in bladder urothelium. These mice were previously shown
to have elevated levels of nuclear p21 in urothelium [19].
Immunohistochemical staining of Pten deficient mouse
bladders and their wild-type littermates showed not only
higher levels of p21 positive cells in the bladder, but also
greatly increased cytoplasmic staining of phospho-GSK3a
and b at serines 9 and 21 (Figure 7). This finding that
GSK-3 exhibits large levels of inhibitory phosphorylation
at sites that are known targets for AKT is consistent with
the idea that GSK-3 inhibition contributes to elevated p21
levels in the Pten-deficient mouse bladder.
Discussion
Deletion of Pten causes increased tumorigenesis in a
mouse model of bladder cancer [19], and there is a great
deal of evidence of decreased PTEN expression in human
bladder carcinomas [4-7]. However, those same studies
on human tumors have suggested that testing PTEN
expression levels in urothelial tumors is not useful for
clinical management, since it does not predict disease
progression or survival. While one reason for this discre-
pancy may be that multiple mechanisms besides dimin-
ished PTEN lead to overstimulation of the PI3-kinase/
AKT pathway [36], we propose that an additional consid-
eration may be the increased expression of p21 in bladder
epithelium when the PI3-kinase pathway is activated. We
have now shown in both the mouse in vivo and in human
urothelial cell lines that stimulation of the PI3-kinase/
AKT pathway leads to an increase in p21 levels. Our stu-
dies in the mouse [19] and multiple studies by others in
human and rat bladder cancer cell lines [37-39] have
shown that induction of p21 inhibits cell proliferation.
Therefore, when bladder cells acquire mutations that
cause overactive PI3-kinase/AKT signaling, the ensuing
p21 expression provides a protective response by sup-
pressing proliferation, and it may delay tumorigenesis.
This p21 induction from PI3-kinase signaling could par-
tially explain why early stage and low grade bladder
tumors demonstrate elevated levels of p21 [25,26],
whereas advanced tumors have reduced p21 expression
[25,28,29]; the p21 provides a protective function and
suppresses tumor growth. Future studies should examine
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Figure 3 Induction of p21 is partially dependent on mTOR. (A) UMUC-3 cells were serum starved for 24 hours and then stimulated with 10
ng/ml EGF in the presence or absence of 1 hour pretreatment with 12.5 nM rapamycin. S6 phosphorylation at serines 235/236 was also
measured to verify rapamycin-mediated inhibition of mTOR. (B) Quantitation of relative p21 induction by EGF in the presence of absence of
rapamycin in UMUC- and UMUC-14 cells. Error bars represent S.E.M.
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Page 7 of 13both the PTEN/PI3-kinase pathway and p21 expression
levels in human tumors simultaneously in order to more
accurately predict the course of disease.
In this paper, we examined both a PTEN negative cell
line, UMUC-3, and a PTEN positive cell line, UMUC-14,
and found similar results in terms of mechanism of p21
induction in both cell types. This does not contradict our
initial finding in mice that p21 induction occurs in the
Pten deficient bladders, because in this paper, the growth
factors such as EGF and PDGF may have overwhelmed
PTEN’s ability to counteract the PI3-kinase stimulation
in the UMUC-14 cells. It is possible that the p21 levels
may eventually fall again in the PTEN positive UMUC-14
cells as PTEN downregulates the PI3-kinase signaling
pathway. It was our observation that in the Pten deficient
animals, the p21 levels remained elevated for over a year.
It is worth noting here that the UMUC-3 cells usually
exhibited superior p21 induction and GSK-3 phosphory-
lation compared to the UMUC-14 cells, which is consis-
tent with the PTEN negative status of UMUC-3 cells.
Nevertheless, these pathways were functional in the
UMUC-14 cells. Our finding that the UMUC-14 cells
were initially more susceptible to LY294002 cytotoxicity
than the UMUC-3 cells was surprising, since UMUC-14
cells show low levels of AKT activation (8). A recent
study indicated that UMUC-14 cells were also more sus-
ceptible than UMUC-3 cells to growth inhibition by
mTOR inhibitor RAD001 [40], hinting at a possible
“addiction” to downstream signaling in the PI3-kinase/
AKT pathway. In the future, these studies should be per-
formed in primary human urothelial cells instead of cell
lines, to rule out the possibility that the mechanisms
A
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Figure 4 EGF stimulates inhibitory phosphorylation of GSK-3a and b in a PI3-kinase and AKT dependent fashion. Phosphorylation of
GSK-3a and b at serines 9 and 21 respectively was tested by immunoblotting of (A) UMUC-3 and UMUC-14 cells that had been serum starved
for 24 hours and then stimulated with 10 ng/ml EGF. Some cells were also pre-treated with 30 μM LY294002 or 10 μM AKTi-1/2 in order to
verify that phosphorylation was dependent on PI3-kinase and AKT activity. (B) Quantitation of relative phospho-GSK-3a and b levels normalized
to tubulin is shown for UMUC-3 and UMUC-14 cells. Four replicates were tested. Error bars represent S.E.M.
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Page 8 of 13observed here do not accurately reflect what occurs in
normal urothelial cells. In addition, cell culture does not
take into effect the possible role of differentiation in
affecting p21 levels.
Our study has shown that GSK-3b may be an important
mechanism by which p21 levels are regulated in the con-
text of PI3-kinase/AKT signaling (Figure 8). It is unclear,
however, if GSK-3b is directly regulating p21 or if the
mechanism is indirect. GSK-3b is known to directly phos-
phorylate substrates such as b-catenin, cyclin D1, and
cyclin D2, leading to ubiquitylation and subsequent
proteasome-dependent degradation of those proteins
[41-43]. It is certainly possible that GSK-3b regulates p21
in this fashion [44] in the bladder cells. We found that
proteasome inhibition of the UMUC-3 cells leads to an
increase in p21, suggesting that p21 levels are regulated by
proteasomal degradation. Ubiquitin-independent proteaso-
mal degradation of p21 has also been described [45]. One
study by Li et al. (2002) [46] suggested that AKT could
directly phosphorylate p21 at Thr 145 to stabilize the pro-
tein, but we were unable to find evidence that p21 was
phosphorylated at this residue. We also found evidence
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Figure 5 GSK-3 regulates p21 expression, and inhibition of GSK-3 reduces cell viabiliity in bladder carcinoma cell lines. (A) UMUC-3
cells were serum-starved, then treated with GSK-3 inhibitor SB216763 (2.5 μM) over a time course and lysates were immunoblotted for p21
expression. Below, p21 levels normalized to tubulin are shown for UMUC-3 and UMUC-14 cells after treatment for five hours with 2.5 μM
SB216763 compared to cells without drug treatment. (B) UMUC-14 cells were transfected with GSK-3a and b expression vectors, and then 48
hours later were serum starved for an additional 24 hours. Cells were subsequently lysed and immunoblotted for GSK-3a and b, p21, b-catenin,
and gapdh. (C) An MTS cell viability assay was run on UMUC-3 and UMUC-14 cells treated with SB216763, LY294002, or a combination of the
two. UMUC-3 cells were tested by MTS assay after 72 hour drug treatment, and UMUC-14 cells were tested after 48 hour treatment. Asterisks
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Page 9 of 13that PI3-kinase signaling partially increases p21 levels
through mTOR activity, most likely due to enhanced pro-
tein synthesis. While work remains to be done in this area,
our studies have defined two pathways, GSK-3b and
mTOR, by which p21 levels are regulated in urothelial
cells during PI3-kinase/AKT signaling.
A fuller understanding of the mechanisms by which
p21 is upregulated by PI3-kinase/AKT signaling will
allow potential therapeutic intervention to increase p21
expression in tumors that have lost it. Although GSK-3b
is generally considered to negatively regulate cell growth,
GSK-3b inhibitors have been found to reduce colon and
ovarian tumor cell growth [47]; these drugs may be
appropriate in bladder cancer because of their effects on
p21. It will be helpful to examine GSK-3b activation
levels in urothelial tumors in order to assess the possible
utility of GSK-3b inhibitors. This pathway should also be
considered where urothelial cancer patients are treated
with PI3-kinase inhibitors, since the decrease in p21 as a
result of the drugs may limit the effectiveness of the ther-
apy. Our studies suggest that combination therapy with
PI3-kinase and GSK-3 inhibitors could be more effective
than PI3-kinase inhibitors alone.
Conclusions
This is the first description of GSK-3b mediated regula-
tion of p21 in bladder cells. We have found evidence
that inhibition of GSK-3b either through activation of
the PI3-kinase/AKT signaling pathway or through the
use of pharmacological inhibitors of GSK-3b leads to an
increase in p21 levels, while an overexpression of GSK-
3b in cells with reduced PI3-kinase/AKT signaling leads
to a decrease in p21. Signaling through mTOR also con-
tributes to the induction of p21. This information will
be useful in predicting outcomes and tailoring che-
motherapy for bladder cancer patients.
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Figure 6 Proteasome inhibition causes an increase in p21. (A) UMUC-3 cells were serum starved for 24 hours and then treated with 1 μM
and 10 μM MG-132 over a 180 minute time course. Cells were lysed and immunoblotted for p21 and tubulin. (B) Quantitation of relative p21
levels normalized to tubulin after 180 minutes treatment with 1 μM MG-132 is shown for UMUC-3 and UMUC-14 cells. Four replicates were
tested. Error bars represent S.E.M.
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15 μm
Figure 7 Pten deletion causes an increase in cytoplasmic phosphorylated GSK-3 a/b ser9/21 in murine bladder epithelium. Sections of
bladder from (A) three day old wild-type Pten
loxp/loxp mice and (B) Pten deficient Fabpl-Cre; Pten
loxp/loxp mice were double immunostained for p21
(brown) and p-GSK-3a/b ser9/21 (pink). Photos were originally taken at 200 × magnification.
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Figure 8 A model for p21 regulation by the PI3-kinase/PTEN signaling pathway. Growth factor signaling stimulates PI3-kinase and induces an
increase in PIP-3 levels at the plasma membrane; PTEN converts PIP-3 back to PIP-2. An increase in PIP-3 causes AKT activation. AKT phosphorylates
GSK-3 causing the inhibition of GSK-3. In the absence of GSK3 activity, p21 levels rise. AKT also activates mTOR, causing an increase in S6
phosphorylation and translation of proteins, which in turn leads to an increase of p21. The p21 causes an inhibition of cell cycle progression.
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